Aurealis Therapeutics, (Basel, Switzerland) and AI-based microbiome drug development company Xbiome have entered into an agreement for the clinical development and commercialisation of Aurealis’ investigational Diabetic Foot Ulcer (DFU) and other chronic wounds and inflammatory disease therapy in the Greater China territory. Click to read more.